Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medica...

Full "IntellAsia: Resources" article